Moreover, TNB-585 has a predicted half-life of over two weeks that enables a patient- and provider-focused dosing schedule." About Teneobio, Inc.

These include TNB-486 (anti-CD19xCD3) and TNB-585 (anti-PSMAxCD3) for the treatments of lymphoma and prostate cancer, respectively. We look forward to filing INDs on these additional programs in ...

This version may not be in its final form and may be updated. Alex Ossola: Here's your TNB Tech Minute for Thursday, January 4th. I'm Alex Ossola for the Wall Street Journal.